MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MOMPARLER, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MOMPARLER, R. L.

Molecular Pharmacology, Vol 8, 362-370, Copyright © 1972 by the American Society for Pharmacology and Experimental Therapeutics

Kinetic and Template Studies with 1-beta-D-Arabinofuranosylcytosine 5'-Triphosphate and Mammalian Deoxyribonucleic Acid Polymerase

RICHARD L. MOMPARLER 1

1 McGill University Cancer Research Unit, Montreal, Quebec, Canada

Kinetic and template studies have been performed with 1-beta-D-arabinofuranosylcytosine 5'-triphosphate (araCTP), dCTP, and calf thymus DNA polymerase. Using denatured DNA as the template, the estimated apparent Km values for araCTP and dCTP were about the same; however, the estimated apparent Vmax value for dCTP was about 8 times greater than the apparent Vmax for araCTP. Both araCTP and dCTP appeared to complete for the same catalytic site of DNA polymerase. When poly(dA-dT) was used as the template, araCTP did not produce any detectable inhibition of the incorporation of [3H]dTTP into acid-insoluble material. DNA Polymerase catalyzed the incorporation of [3H]araCTP into poly dC:poly dG, but not into poly(dA-dT). DNA containing [agr-32P]arabinofuranosylcytosine 5'-monophosphate ([agr-32P]araCMP) was synthesized enzymatically, using denatured DNA and DNA polymerase. Following the digestion of this [32P]DNA with micrococcal nuclease and spleen phosphodiesterase to deoxynucleoside 3'-monophosphates, the radioactivity from [agr-32P]araCMP appeared in 3'-dAMP, 3'-dGMP, 3'-dTMP, and 3'-dCMP, suggesting that DNA polymerase could catalyze the formation of a phosphodiester bond between araCMP and each of the deoxynucleotides present in the DNA template.

The data from studies on the rate of release of [agr-32P]araCMP and [3H]dCMP from DNA by snake venom phosphodiesterase and the incorporation of araCTP and dCTP into denatured, sonicated DNA are consistent with the proposal that the incorporation of araCTP into DNA in the reaction catalyzed by DNA polymerase produces termination of polynucleotide chain growth.

Note:
ACKNOWLEDGMENT I would like to thank Miss Aurora Labitan for her excellent technical assistance in this work.

Submitted on December 7, 1971







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1972 by the American Society for Pharmacology and Experimental Therapeutics